September 25-26, 2020

Virtual, Interactive Conference!

Friday, September 25, 2020 - 1:00 PM - 5:00 PM EDT

Saturday, September 26, 2020 - 8:00 AM - 4:55 PM EDT

At this pan-tumor, interactive symposium, discussions will encompass the latest topics in major solid and liquid tumors. This meeting will cover key malignancies, including lung cancers, breast cancers, gastrointestinal cancers, genitourinary cancers, skin cancers, and hematologic malignancies, and feature keynote lectures focusing on precision medicine. High-impact sessions will focus on practical takeaways regarding the latest updates in next-generation sequencing, liquid biopsy, and cytogenetic testing. The expert faculty will review updates in targeted treatment, including tumor-agnostic indications based solely on genomic markers and other biomarkers. This program will emphasize the role of advanced genetic panel testing and the use of targeted therapies, as well as best practices for leveraging relevant actionable targets that drive clinical decision making, with a focus on data that is most relevant for patient care.

• Learn from the experts how to interpret tumor pathology reports to facilitate evidence-based treatment across malignancies
• Improve your knowledge about diagnostic and treatment-related data relevant to optimal multidisciplinary care
• Gain expert perspectives on the most relevant data regarding the current and evolving role of genomic assays in cancer management
• Learn about the latest clinical data regarding the use of biomarkers in qualifying patients for specific oncolytic therapies

This activity is supported by educational grants from AstraZeneca; Exact Sciences Corporation; Eisai Inc.; Genomic Health; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Seattle Genetics, Inc.

This educational activity is directed toward pathologists and oncologists, as well as nurses and fellows, involved in the treatment and management of patients with cancer. Physician assistants, pharmacists, researchers, and other healthcare professionals may also participate.

Upon successful completion of this activity, you should be better prepared to:

1. Evaluate clinical data regarding the use of biomarkers in qualifying patients for specific oncolytic therapies
2. Interpret tumor pathology reports to facilitate evidence-based treatment across malignancies
3. Summarize diagnostic and treatment-related data relevant to optimal multidisciplinary care
4. Evaluate the most relevant data regarding the current and evolving role of genomic assays in cancer management